# US 2025/0154465 A1 · Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154465 A1
- Document ID: US20250154465A1
- Status: Published application
- Kind: A1
- Application number: 19/034,027
- Filed: 2025-01-22
- Published: 2025-05-15
- Earliest claimed: 2020-01-28
- Assignees: ImmunityBio, Inc.
- Applicants: ImmunityBio, Inc.
- Inventors: John H. Lee; Laurent H. Boissel; Hans G. Klingemann
- Web page: https://patentgrep.com/patent/US20250154465A1

## CPC

- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4204: {Epidermal growth factor receptors [EGFR]}
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/485: Epidermal growth factor [EGF], i.e. urogastrone
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/5434: {IL-12}
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- C07K 14/71: for growth factors; for growth regulators
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/32: against translation products of oncogenes
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/50: Colon
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/53: Hinge
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are genetically modified NK cells expressing a chimeric antigen receptor targeting an EGFR superfamily receptor. The CAR can comprise an intracellular domain of FcεRIγ and further recombinant proteins expressed by the genetically modified NK cells are CD16, autocrine growth stimulating cytokines, and optionally one of IL-12, a TGF-beta trap, or a homing receptor. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient the genetically modified NK cells.

## Claims

### Claim 1

A genetically modified NK cell comprising one or more recombinant nucleic acids encoding and expressing
(i) a membrane bound recombinant chimeric antigen receptor (CAR) that comprises in a single polypeptide chain an extracellular binding domain that specifically binds to an EGFR superfamily receptor, a hinge domain, a transmembrane domain, and a FcεRIγ signaling domain having at least 90% sequence identity to the polypeptide sequence of SEQ ID NO:1;
(ii) a suicide gene product that allows the genetically modified NK cell expressing the suicide gene to be killed by contacting the genetically modified NK cell with a selective agent; and
(iii) a recombinant CD16 and/or an autocrine growth stimulating cytokine.

### Claim 2 (depends on 1)

The genetically modified NK cell of claim 1, wherein the EGFR superfamily receptor is EGFR.

### Claim 3 (depends on 2)

The genetically modified NK cell of claim 2, wherein the extracellular binding domain has at least 90% sequence identity to the polypeptide sequence of SEQ ID NO:41.

### Claim 4 (depends on 1)

The genetically modified NK cell of claim 1, wherein the EGFR superfamily receptor is HER2/neu.

### Claim 5 (depends on 4)

The genetically modified NK cell of claim 4, wherein the extracellular binding domain has at least 90% sequence identity to the polypeptide sequence of SEQ ID NO:43.

### Claim 6 (depends on 1)

The genetically modified NK cell of claim 1, wherein the genetically modified NK cell expresses the recombinant CD16 and the autocrine growth stimulating cytokine, and optionally wherein the recombinant CD16 is a CD16158V mutant.

### Claim 7 (depends on 1)

The genetically modified NK cell of claim 1, wherein the autocrine growth stimulating cytokine is IL-2 or IL-15, and optionally wherein the autocrine IL-2 or IL-15 further comprises an endoplasmic retention sequence.

### Claim 8 (depends on 1)

The genetically modified NK cell of claim 1, wherein the suicide gene is selected from the group consisting of a thymidine kinase (TK) gene, a cytosine deaminase (CD) gene, a nitroreductase (NR) gene, a xanthine-guanine phosphoribosyl transferase (E. coli gpt) gene, a purine nucleoside phosphorylase (E. coli Deo) gene, a cytochrome P450 gene, or an inducible caspase-9 (iCasp9) gene.

### Claim 9 (depends on 1)

The genetically modified NK cell of claim 1, wherein the nucleic acid further encodes and the cell expresses one of IL-12, a TGF-beta trap, or a homing receptor.

### Claim 10 (depends on 9)

The genetically modified NK cell of claim 9, wherein the IL-12 is a single chain IL-12 heterodimer.

### Claim 11 (depends on 9)

The genetically modified NK cell of claim 9, wherein the TGF-beta trap comprises a single chain dimer of the TGF-beta Receptor II ectodomain, or wherein the TGF-beta trap is a secreted form of a single chain dimer of the TGF-beta Receptor II ectodomain.

### Claim 12 (depends on 9)

The genetically modified NK cell of claim 9, wherein the homing receptor is selected from the group consisting of CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7, CX3CR1, XCR1, CCXCKR, D6, DARC, and a receptor for CXCL14.

### Claim 13 (depends on 1)

The genetically modified NK cell of claim 1, wherein the FcεRIγ signaling domain has the polypeptide sequence of SEQ ID NO:1.

### Claim 14 (depends on 1)

The genetically modified NK cell of claim 1, wherein the extracellular binding domain has at least 90% sequence identity to the polypeptide sequence of SEQ ID NO:41, or wherein the extracellular binding domain has at least 90% sequence identity to the polypeptide sequence of SEQ ID NO:43.

### Claim 15 (depends on 1)

The genetically modified NK cell of claim 1, wherein the extracellular binding domain has the polypeptide sequence of SEQ ID NO:41, or wherein the extracellular binding domain has the polypeptide sequence of SEQ ID NO:43.

### Claim 16 (depends on 15)

The genetically modified NK cell of claim 15, wherein the suicide gene is selected from the group consisting of a thymidine kinase (TK) gene, a cytosine deaminase (CD) gene, a nitroreductase (NR) gene, a xanthine-guanine phosphoribosyl transferase (E. coli gpt) gene, a purine nucleoside phosphorylase (E. coli Deo) gene, a cytochrome P450 gene, or an inducible caspase-9 (iCasp9) gene.

### Claim 17 (depends on 1)

A method of treating cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the genetically modified NK cells of claim 1 and thereby treating the cancer, wherein the genetically modified NK cell is autologous or allogeneic to the patient.

### Claim 18 (depends on 17)

The method of claim 17 further comprising a step of administering at least one additional therapeutic entity selected from the group consisting of a viral cancer vaccine, a bacterial cancer vaccine, a yeast cancer vaccine, N-803, an antibody, a stem cell transplant, and a tumor targeted cytokine.

### Claim 19 (depends on 17)

The method of claim 17, wherein the cancer is a lung cancer, a breast cancer, a thyroid cancer, an esophageal cancer, a gastric cancer, a gastroesophageal cancer, or a head and neck cancer.

### Claim 20 (depends on 17)

The method of claim 17, wherein about 1×108 to about 1×1011 cells per m2 of body surface area of the patient are administered to the patient.
